Why pharmaceutical sovereignty must become a national priority
Indonesia covers nearly its entire population under national health insurance, yet relying on imports for 90 percent of its active medicine ingredients leaves the country dangerously exposed to the next global shock.
Indonesia's national health insurance program, BPJS Kesehatan, covers nearly all residents, yet the country's heavy reliance on imported pharmaceutical ingredients poses significant risks. Around 90% of active medicine ingredients are sourced from China, India, Europe, and other nations, leaving Indonesia vulnerable to global supply chain disruptions.
This asymmetrical dependence on foreign suppliers makes the country's healthcare security precarious, especially during geopolitical tensions, export restrictions, or shipping bottlenecks. Even a minor disruption can jeopardize the availability of life-saving medicines nationwide. As other major economies pursue pharmaceutical nationalism, global competition for manufacturing capacity intensifies, leaving developing nations at a disadvantage.
Indonesia's domestic healthcare needs are substantial, with diabetes projected to account for 5.6% of monthly healthcare cases, while acute respiratory infections represent 8.9%. However, the National Formulary only includes around 2% of innovative medicines. Limited domestic industrial policy has hindered the growth of the country's pharmaceutical sector, making it reliant on expensive imported ingredients.
To achieve true pharmaceutical sovereignty, Indonesia must prioritize domestic production and diversify its supply sources, addressing both healthcare accessibility and long-term security.
Written by urgent.news from The Jakarta Post's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
